Insider Buying: Rapport Therapeutics (NASDAQ:RAPP) CFO Purchases $143,550.00 in Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) CFO Troy Ignelzi purchased 5,500 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, October 21st. The stock was bought at an average cost of $26.10 per share, with a total value of $143,550.00. Following the completion of the transaction, the chief financial officer owned 15,500 shares of the company’s stock, valued at $404,550. The trade was a 55.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Rapport Therapeutics Stock Down 2.3%

Shares of RAPP stock opened at $25.93 on Friday. The stock’s 50-day moving average is $39.01 and its two-hundred day moving average is $38.93. Rapport Therapeutics, Inc. has a 1 year low of $23.75 and a 1 year high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). Research analysts forecast that Rapport Therapeutics, Inc. will post -4.08 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on RAPP. William Blair began coverage on Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating for the company. JonesTrading raised their target price on shares of Rapport Therapeutics from $50.00 to $82.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen cut shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. UBS Group initiated coverage on shares of Rapport Therapeutics in a research report on Thursday, October 15th. They issued a “buy” rating and a $71.00 price target for the company. Finally, Wolfe Research assumed coverage on shares of Rapport Therapeutics in a research note on Thursday, October 15th. They set an “outperform” rating and a $50.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Rapport Therapeutics currently has an average rating of “Buy” and a consensus target price of $68.36.

Trending Headlines about Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
• Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
• Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
• Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

Institutional Investors Weigh In On Rapport Therapeutics

Hedge funds have recently modified their holdings of the stock. KBC Group NV acquired a new stake in shares of Rapport Therapeutics during the first quarter worth $30,000. Sterling Capital Management LLC increased its stake in Rapport Therapeutics by 597.9% in the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock valued at $33,000 after buying an additional 843 shares during the period. State of Wyoming acquired a new position in Rapport Therapeutics in the 2nd quarter valued at $65,000. Meeder Asset Management Inc. acquired a new position in Rapport Therapeutics in the 2nd quarter valued at $116,000. Finally, AlphaCentric Advisors LLC raised its position in Rapport Therapeutics by 6.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after buying an additional 408 shares during the last quarter.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.